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PHARMACOECONOMIC EVALUATION OF 
USAGE OF UNFRACTIONATED HEPARIN AND 
LOW MOLECULAR WEIGHT HEPARIN IN THE 
TREATMENT OF DEEP VEIN THROMBOSIS IN 
LONG-TERM CARE RESIDENTS
Karki SD1, Bellnier TJ1, Karki J1, Patterson W2, Masood R2
1SUNY University at Buffalo School of Pharmacy, Buffalo, NY, 
USA; 2Clifton Springs Hospital & Clinics, Clifton Springs, NY, USA
OBJECTIVE: Nursing home residents with acute proxi-
mal deep-vein thrombosis (DVT) are usually transferred
to the hospital and treated initially with unfractionated
heparin administered by continuous infusion for five to
seven days. The anticoagulant response to this treatment
varies markedly among patients and therefore the dosage
must be adjusted by measuring the activated partial-
thromboplastin time closely. With the availability of low
molecular weight heparins and their proven efficacy and
safety in treatment and prophylaxis of deep vein throm-
bosis and no need to closely monitor any parameter and
adjust the dosage, it has become possible to treat DVT in
nursing home setting. We describe our findings of the eco-
nomic implications of two different therapies. METHOD:
All residents treated for DVT in the last 2 years were
identified and their charts reviewed as to the use of hep-
arin or enoxapirin (formulary LMWH in our institution).
Charts of 25 residents from each group matched for sex
and age were randomly reviewed as to efficacy, transfer
to hospital, days of hospitalization and costs of treat-
ment. RESULTS: The residents, in the heparin arm, were
transferred to the hospital, treated with continuous hep-
arin infusion, initiated on warfarin therapy and then
transferred back to the nursing home. The hospitalization
ranged from 5–15 days and the mean hospitalization cost
was $4196  225. Of the residents on enoxapirin arm,
only 9 residents were transferred to the hospital and the
hospitalization ranged from 3–5 days. The mean hospi-
talization and nursing home costs were $2258  150.
There was additional drug cost $490 in the heparin arm
and $800 in the of enoxapirin arm resulting in cost sav-
ing of $1628 per resident in the enoxapirin arm CON-
CLUSION: Our results indicate that enoxapirin is cost-
effective in the treatment of DVT in the nursing home
residents.
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BEYOND THE FIRST YEAR: PATTERNS AND 
PREDICTORS OF LONG-TERM STATIN 
UTILIZATION
Benner JS1, Federman AD1, Smitten AL2, Duty S2, Glynn RJ1, 
Avorn J1
1Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA, USA; 2Harvard School of Public Health, Boston, 
MA, USA
INTRODUCTION: Noncompliance with lipid-lowering
medications has important implications for clinical and
economic outcomes of therapy. Little is known about
long-term utilization of HMG Co-A reductase inhibitors
(statins) because previous data have been based on
closely monitored trials or have observed patients for
short periods of time. OBJECTIVE: To describe patterns
and predictors of long-term compliance with statin ther-
apy in a US elderly population. METHODS: Cohort
study (n  607) of enrollees in the New Jersey Medicaid
and Pharmacy Assistance for the Aged and Disabled
(PAAD) programs aged 65 and older who began statin
therapy in the first half of 1990. Filled prescription data
were used to assess the proportion of days with any statin
available in each of 12 consecutive 6-month intervals af-
ter initiation of therapy. Demographic and clinical pre-
dictors of noncompliance, measured at baseline, were
identified using linear models for repeated measures. RE-
SULTS: Mean days with statin available was 64% in the
first 6 months of therapy and 45% in the next 6 months;
it then decreased linearly to 32% at the end of year 6.
The proportion of patients with 80% of days covered
was 41% in the first 6 months, 30% in the next 6
months, and 25% at the end of year 6. After controlling
for baseline demographic and clinical variables, lower
compliance in years 2 through 6 was significantly associ-
ated with duration of treatment, black race, lower in-
come, older age, and taking fewer other medications. By
contrast, first-year compliance was significantly better
among blacks than other races and age was not associ-
ated with utilization. CONCLUSIONS: Compliance with
statin therapy declines over time, with the greatest reduc-
tions occurring in the first year of treatment. Predictors
of short- and long-term compliance differ, with long-term
noncompliance most strongly predicted by age, race, and
socioeconomic status.
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CHD RISK FACTORS AND THERAPY DURATION 
OF HMG-COA REDUCTASE INHIBITORS 
(STATINS) IN A MEDICAID POPULATION
Nichol MB1, Bron MS1, Yu W2
1University of Southern California, Los Angeles, CA, USA; 
2Wellpoint Pharmacy Management, Thousand Oaks, CA, USA
INTRODUCTION: The purpose of this research is to
explore the relationship between the number of CHD
risk factors (RF) and duration of therapy of statins. CHD
risk factors play an important role in choice and goals of
lipid-lowering therapy. OBJECTIVE: To determine if the
median duration of therapy differs among Medicaid hy-
percholesteremic patients with 0,1,2 and 3 or greater
CHD risk factors who were treated with statins currently
on formulary. METHODS: Retrospective database anal-
ysis of pharmacy claims data for an intent-to-treat analy-
sis of Medicaid monotherapy statin patients. Patients
were required to be eligible 35 days before and 365 days
after the first statin prescription. New patients (n  767)
must have a 90 day washout period. Continuing patients
(n  1191) do not. The Medians test was used for non-
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parametric data. OLS regression tested the relationship
between duration of therapy and presence of CHD risk
factors. RESULTS: For each statin, days on therapy dif-
fered significantly (p  0.001) by the number of risk fac-
tors. The number of CHD risk factors was positively sig-
nificant in predicting duration of therapy (p  0.0001) in
both new and continuing therapy. Duration of therapy
was associated with an increase of 48 days for each risk
factor for new patients and 58 days for continuing pa-
tients.CONCLUSIONS: Number of CHD risk factors is
positively correlated with length of therapy when using
statins as lipid lowering therapy for new and continuing
patients.
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CARING FOR HYPERTENSION ON INITIATION: 
COSTS AND EFFECTIVENESS (CHOICE). DESIGN 
AND RATIONALE OF A NATURALISTIC STUDY
Payne K1, Caro J1, Hollenberg N2, Jackson J3, L’Italien G3, for 
the CHOICE Study Group
1Caro Research Institute, Dorval, QC, Canada; 2Harvard 
Medical School and Brigham and Women’s Hospital, Boston, 
MA, USA; 3Bristol-Myers Squibb, Princeton, NJ, USA
INTRODUCTION: Naturalistic studies are essential to
prospectively study real-world antihypertensive treat-
ment OBJECTIVE: to evaluate the feasibility of perform-
ing a naturalistic study in newly diagnosed hypertensives
in terms of enrollment, adequacy, timeliness of data col-
lection, and study procedures. METHODS: CHOICE
prospectively collected actual practice data on the treat-
ment of newly-diagnosed hypertensive patients. Initial
therapy was randomly assigned to either Group 1 (beta
blockers or diuretics) or Group 2 (ACE inhibitors or cal-
cium channel blockers). The protocol made no demands
in scheduling visits or changing treatment during follow-
up. Physicians were blind to study purpose and hypothe-
ses. Only a final visit at 5  1 months, if none occurred
naturally, was mandated. Direct involvement of the
CHOICE study team was minimized using a Remote
Study Monitoring System to collect data and communi-
cate with study sites. RESULTS: Within 30 weeks, a total
of 55 physicians enrolled 512 patients with a mean age of
51 years and blood pressure of 158/99 mmHG. In all, 46
different antihypertensive medications were prescribed
and 2,554 office visits (range  1–16 visits per patient)
were attended. Other medical resource use was low dur-
ing the study period. A final, clean database was ready
for analysis 30 days after last patient last visit. CON-
CLUSIONS: It has been demonstrated that CHOICE is a
Statin Risk Factors (RF): 0 RF: 1 RF: 2 RF: 3 OR 4
Overall Median 305 431 481 550
atorvastatin 345 419 424 562
fluvastatin 289 428 505 568
pravastatin 303 444 469 533
feasible framework to study the real-world effectiveness
of initial therapy for newly diagnosed hypertension. Pro-
tocol flexibility and a novel electronic data entry system
are core elements of this naturalistic design.
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A PHARMACOECONOMIC MODEL TO 
EVALUATE TREATMENT OPTIONS FOR DVT 
PHARMACOPROPHYLAXIS
Spruill WJ, Wade WE, Leslie RB
University of Georgia College of Pharmacy, Athens, GA, USA
Economic analysis of various treatment modalities used
to prevent deep vein thrombosis (DVT) in various medi-
cal and surgical at-risk patients has been limited by lack
of consistent and representative methods to evaluate vari-
ous resource costs attributed to both the prevention of
DVT and the diagnosis and treatment of prophylaxis fail-
ures. OBJECTIVE: To develop a systematic and compre-
hensive method to identify and prioritize all direct costs
associated with DVT prophylaxis. METHODS: A deci-
sion tree was developed to identify and prioritize all med-
ical, surgical and diagnostic procedures that contribute to
overall direct cost. Included were costs of prophylaxis,
cost of diagnosing a prophylaxis failure (a DVT) and
costs of major complications of this therapy (pulmonary
embolism, major bleeding and thrombocytopenia.) Diag-
nostic procedures were also prioritized clinically as either
a “standard”, “alternative or confirmatory”, or “supple-
mental” procedure. This prioritization allows for proba-
bility multipliers to be assigned to each category of diag-
nostic procedures in order to get a weighted average of
the cost of this procedure. Likewise, the various costs as-
sociated with prophylaxis failure were prioritized. Next a
spreadsheet was developed to match this decision tree.
This spreadsheet contained all identified resource costs
shown on the decision tree and indicated the quantity or
units of each resource that are typically used. Lastly, the
corresponding CPT and ICD9 codes for all resources
were identified. RESULTS: Major categories of resources
identified include diagnostic, treatment, and monitoring.
These 3 areas are divided into 13 sub-categories which in
turn include over 60 specifically identified cost related re-
sources. CONCLUSION: This model allows any institu-
tion to accurately identify, prioritize and analyze institu-
tion specific resource costs instead of using literature
values to determine the cost-benefit of various pharma-
coprophylactic regimens including unfractionated hep-
arin and various low molecular weight heparins used at
their site.
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CHOLESTEROL REDUCTION SUCCESS RATES 
AND RESOURCE UTILIZATION BY GENDER
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